




# Full Year 2024 Financial Results



Total Revenues

**\$14.7B**

Ex Divestitures: ~\$14.25B\*

Adjusted EBITDA\*

**\$4.7B**

Ex Divestitures: ~\$4.4B\*

Free Cash Flow\*

Excluding Transaction Costs

**\$2.6B**

Ex Divestitures: ~\$2.3B\*

Adjusted EPS\*

**\$2.65**

Ex Divestitures: ~\$2.50\*

Full Year Divestiture-Adjusted Operational Revenue Growth of 2%\*



"2024 was a good year for Viatris with full year operational revenue growth of 2%, excluding divestitures, in line with our guidance. As we head into 2025, we are focused on driving strong commercial execution, advancing our pipeline—including several important late-stage development milestones for selatogrel, cenerimod and sotagliflozin and six Phase 3 readouts—prioritizing capital return with a focus on share repurchases, executing our remediation plan for Indore and beginning an enterprise-wide initiative to review our global infrastructure and identify additional cost savings."

– Scott A. Smith  
Chief Executive Officer

## Delivered on Our Strategic Pillars in 2024



### DIVERSIFIED & GROWING BASE BUSINESS

Seventh consecutive quarter of divestiture-adjusted operational revenue growth\*

Delivered new product revenues of \$582M in 2024

Completed planned divestitures to simplify and streamline our organization



### FINANCIAL STRENGTH & SIGNIFICANT CASH FLOW

Generated free cash flow of \$2.6B in 2024<sup>(1)</sup>

Returned \$825M in capital to shareholders through dividend and share repurchases

Retired ~\$3.7B of debt in 2024 and achieved long-term gross leverage target, ending the year at 2.9x\*



### EXPANDING INNOVATIVE PORTFOLIO

Idorsia collaboration added two Phase 3 assets, selatogrel and cenerimod, both with blockbuster potential

Entered into exclusive licensing agreement for sotagliflozin in all markets outside of the U.S. and Europe

## Building Sustainable Access at Scale



Supplying high-quality medicines to ~1 billion patients around the world annually<sup>(2)</sup>

\*Non-GAAP Financial Measure. For more information about Non-GAAP financial measures and reconciliations to the closest U.S. GAAP financial measure, as well as risks related to forward-looking statements, please read our [Fourth Quarter and Full Year 2024 Financial Results press release](#) on our website.

<sup>(1)</sup> 2024 Free Cash Flow was \$2.0B. Excluding the impact of transaction costs primarily related to the divestitures of \$649M, 2024 Free Cash Flow was \$2.6B.

<sup>(2)</sup> See our 2023 Sustainability Report page 4 for more information.



[Viatris.com](#)



[LinkedIn](#)



[@ViatrisInc](#)



[@ViatrisInc](#)



[YouTube](#)



[Listen Well Podcast](#)

© 2025 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris Company.